AN2 Total Current Liabilities from 2010 to 2024
| ANTX Stock | USD 1.67 0.30 21.90% |
Total Current Liabilities | First Reported 2010-12-31 | Previous Quarter 14 M | Current Value 14.7 M | Quarterly Volatility 5.1 M |
Check AN2 Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AN2 Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 73.1 M, Interest Expense of 620.7 K or Selling General Administrative of 7.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.68. AN2 financial statements analysis is a perfect complement when working with AN2 Therapeutics Valuation or Volatility modules.
AN2 | Total Current Liabilities |
Latest AN2 Therapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of AN2 Therapeutics over the last few years. Total Current Liabilities is an item on AN2 Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of AN2 Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. AN2 Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AN2 Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
AN2 Total Current Liabilities Regression Statistics
| Arithmetic Mean | 2,827,877 | |
| Geometric Mean | 531,411 | |
| Coefficient Of Variation | 179.37 | |
| Mean Deviation | 3,741,019 | |
| Median | 159,000 | |
| Standard Deviation | 5,072,461 | |
| Sample Variance | 25.7T | |
| Range | 14.6M | |
| R-Value | 0.75 | |
| Mean Square Error | 12.2T | |
| R-Squared | 0.56 | |
| Significance | 0 | |
| Slope | 847,807 | |
| Total Sum of Squares | 360.2T |
AN2 Total Current Liabilities History
About AN2 Therapeutics Financial Statements
AN2 Therapeutics investors use historical fundamental indicators, such as AN2 Therapeutics' Total Current Liabilities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AN2 Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 14 M | 14.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.